Novo Nordisk is bringing another round of real-world evidence on its Wegovy pill to ObesityWeek 2026, and much of it comes from an unusual place. At the meeting, which runs November 14 to 17 in National Harbor, Maryland, Novo plans to present three analyses from OCTANE, a study using data from adults who started oral semaglutide through the Ro telehealth platform. The posters are scheduled for the afternoon of November 15. The new findings remain embargoed, and Novo’s October 29 announcement of its 26-abstract program included no outcome numbers for these presentations.
That makes this a preview, not a results story. It is also not the first release from OCTANE. In September, Novo reported three-month findings among Ro patients who switched from injectable weight-loss medications to oral semaglutide and remained on treatment. The newly scheduled analyses will broaden the picture to include early initiators, weight outcomes, food noise and patient-reported experience.
The shape of what Novo chose to bring is revealing. The Wegovy pill, a 25 mg once-daily oral form of semaglutide, competes with Eli Lilly’s Foundayo, and some of the evidence now being presented comes not from another randomized trial but from observational analyses of patients receiving care through a direct-to-patient digital platform.
What Novo is bringing to ObesityWeek on the Wegovy pill
According to Novo’s release, OCTANE examines adults starting oral semaglutide for weight management, including people who had never previously taken an obesity medication. Three posters will cover the characteristics of early starters, weight outcomes at three months, and food noise alongside other patient-reported outcomes at three months.
“Food noise,” the intrusive preoccupation with eating that many patients describe, has become a marketing touchstone for GLP-1 drugs. It is notable to see patient experience sharing space with weight outcomes in the presentation schedule. But whether changes in food noise were measured consistently, and how much missing follow-up data might affect the findings, will matter when the abstracts become public.
A fourth poster comes from SWEEP, a cohort drawn from Novo’s digital patient support program. It examines self-reported weight-related outcomes and patient experience among people starting the pill. A fifth, from OPTIC, compares preferences for obesity medication characteristics among adults aged 65 and older versus younger adults. All five posters are scheduled for November 15, from 2:30 to 3:30 p.m. Eastern.
There is already a useful OCTANE reference point. On September 30, Novo reported that patients switching from injectable semaglutide or tirzepatide to the Wegovy pill lost an average of 4.1% of body weight over three months. Crucially, the analysis required patients to remain on oral treatment throughout that period and have weight data available. Those conditions make its findings informative about a selected group of continuing users, not everyone who initially started the pill.
Three months of telehealth data can show early treatment outcomes. It cannot establish who stays on therapy over the long term.
Why the source of the data matters
Real-world studies are valuable because randomized trials enroll carefully screened volunteers who receive protocol-driven monitoring and support. Outside trials, people miss doses, stop when the price changes, switch therapies and take medications alongside everything else in their lives. For a daily pill competing against weekly injections, how treatment fits into ordinary routines is a fair question.
But a cohort assembled through a telehealth platform and a manufacturer’s own patient support program represents a particular slice of the population. Patients who enroll through digital services may differ from patients receiving conventional in-person care in motivation, access, health literacy, financial circumstances and willingness to report outcomes. Those differences can affect the interpretation of observational findings.
There is also the question of measurement. Novo has explicitly identified self-reported data, incomplete routine-care records and selection bias from treatment-persistence requirements as limitations of its previously reported OCTANE analysis. Whether the November cohorts use comparable methods, how many patients are missing follow-up weights, and how discontinuation is handled will need examination when the new results are released.
Three months is short for a chronic therapy. Novo’s REDEFINE 9 CagriSema trial, for comparison, followed treatment outcomes through 68 weeks. Different studies answer different questions, but a brief observational snapshot cannot substitute for evidence about long-term persistence and durability.
Readers who followed our analysis of Wegovy pill versus Foundayo market share data will recognize the pattern: in the oral GLP-1 race, who generates the evidence and which patients are included can shape the headline.
Self-reported outcomes from a manufacturer-linked support cohort are a starting point, not a verdict.
CagriSema and children also on the program
The rest of Novo’s ObesityWeek slate leans on its pipeline and pediatric research. The company will present detailed findings from REDEFINE 9, which tested lower once-weekly doses of CagriSema, its investigational combination of the amylin analog cagrilintide and semaglutide, at 1.0/1.0 mg and 1.7/1.7 mg.
Those results are not entirely new. Novo announced topline findings in September, reporting approximately 21% average weight loss at 68 weeks with the 1.0/1.0 mg dose under the trial’s efficacy estimand. The November presentation should provide a fuller account of the trial, including questions about tolerability, dose flexibility and the weight-loss response across groups. We previously covered the study in our CagriSema REDEFINE 9 analysis.
Four additional analyses connected to the earlier REDEFINE 1 trial examine physical and psychosocial function, outcomes by baseline BMI and complications, and early weight-loss trajectories. Another analysis models CagriSema’s potential effect on first cardiovascular events in the United States. Modeling is not evidence that a clinical cardiovascular benefit has been demonstrated. CagriSema remains investigational and is not approved anywhere.
On November 16, Novo will deliver an oral presentation of the STEP Young trial of injectable semaglutide in children aged 6 to under 12 with obesity. The full findings are scheduled for simultaneous publication. Headline results released in September reported that 40.4% of children receiving semaglutide no longer met the obesity classification at week 68, compared with none receiving placebo, using the trial-product estimand. Both groups received lifestyle interventions.
That is an important preliminary result, but the full analysis will matter for understanding treatment discontinuation, adverse events, growth and pubertal development. Semaglutide is not approved in the United States for obesity treatment in children under 12.
The Lilly comparison hiding in the abstracts
An independent November 3 preview by Life Science Daily highlighted another item in Novo’s program: a short-term cost-of-control evaluation comparing oral semaglutide with orforglipron, the Lilly pill marketed as Foundayo. The abstract is listed as ORACLE.
Economic modeling abstracts are common at medical meetings, but a comparison involving a manufacturer’s direct oral competitor deserves close attention to assumptions about medication prices, dose schedules, efficacy inputs, treatment duration and what counts as achieving control. A favorable model is not necessarily a favorable real-world outcome, particularly if its assumptions do not resemble how patients actually obtain or take the drug.
The wider competition will also be visible at the meeting. On November 9, Viking Therapeutics announced two poster presentations involving its investigational dual GLP-1/GIP agonist VK2735. One covers baseline characteristics of the VANQUISH-2 Phase 3 study; another examines obesity severity and cardiometabolic parameters in an analysis of the earlier VENTURE study. Neither announcement establishes a new head-to-head comparison with the Wegovy pill.
Novo’s chief scientific officer, Martin Holst Lange, framed the company’s conference program around differing patient experiences and treatment needs. The emphasis on age-stratified preferences, food noise and telehealth initiators suggests that Novo wants the conversation about its oral formulation to extend beyond maximum weight loss and toward the realities of how patients use treatment.
The oral GLP-1 competition is moving beyond trial charts into patient-experience data. The quality of that evidence matters.
What to watch on November 15
When the ObesityWeek embargo lifts at noon Eastern on November 14, the key details to examine will be sample sizes, how patients were selected, how many remained on therapy at three months, whether weights were measured or self-reported, what share reached the full 25 mg dose, and how gastrointestinal adverse events were captured.
Those details will determine whether the new OCTANE analyses add meaningful evidence about everyday oral semaglutide use or primarily describe the early experience of patients enrolled through a particular telehealth channel.
The bigger question is durability. Obesity pharmacotherapy generally requires long-term management, and persistence outside controlled trials remains a major issue for patients, clinicians and payers. A three-month snapshot cannot establish whether the treatment’s benefits continue over a year or longer, particularly if patients who stop therapy are missing from the analysis.
Still, these presentations could expand the early real-world picture beyond the injection-to-pill switchers previously reported by Novo. Including treatment-naive starters and patient-reported experience may answer questions that the September OCTANE findings could not.
That is worth reading closely rather than accepting a favorable press-release headline at face value. Grey Pepper will assess what the new data actually show when they become public.
Sources
- Novo Nordisk — ObesityWeek 2026 program announcement, October 29, 2026.
- Novo Nordisk — OCTANE real-world Wegovy pill findings presented at EASD, September 30, 2026.
- Novo Nordisk — CagriSema REDEFINE 9 topline findings, September 21, 2026.
- Novo Nordisk — STEP Young topline findings, September 7, 2026.
- Life Science Daily — ObesityWeek 2026 Preview: The Data to Watch in Washington, November 3, 2026.
- Viking Therapeutics — Two poster presentations at ObesityWeek 2026, November 9, 2026.
- ObesityWeek — Official 2026 embargo policy.
